Cytosorbents (NASDAQ:CTSO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They currently have a $10.00 target price on the medical research company’s stock.
A number of other research analysts also recently commented on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Thursday, May 15th. Wall Street Zen began coverage on shares of Cytosorbents in a report on Wednesday, May 21st. They issued a “hold” rating for the company.
Get Our Latest Stock Report on CTSO
Cytosorbents Stock Performance
Cytosorbents (NASDAQ:CTSO – Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.01 million. Cytosorbents had a negative return on equity of 105.04% and a negative net margin of 41.77%. Equities analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Millennium Management LLC bought a new stake in Cytosorbents in the fourth quarter worth about $30,000. Goldman Sachs Group Inc. increased its position in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the period. Key Client Fiduciary Advisors LLC increased its holdings in Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock valued at $78,000 after buying an additional 43,900 shares during the period. Renaissance Technologies LLC increased its holdings in Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares during the period. Finally, Northern Trust Corp increased its holdings in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the period. Institutional investors own 32.87% of the company’s stock.
Cytosorbents Company Profile
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Recommended Stories
- Five stocks we like better than Cytosorbents
- Using the MarketBeat Dividend Yield Calculator
- Astera Labs: AI Infrastructure Play With Significant Growth Ahead
- Why Are Stock Sectors Important to Successful Investing?
- Is IBM’s AI Transformation Powering a Sustained Rally?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- NVIDIA’s Stock Price Hits New Highs: This Is What’s Next
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.